TIDMODX

RNS Number : 9407U

Omega Diagnostics Group PLC

18 July 2018

Omega Diagnostics Group PLC

("Omega" or "the Company")

VISITECT(R) CD4 commercialisation update

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update on its VISITECT(R) CD4 commercialisation programme.

The Company announces the appointment of three new dedicated distributors in Ghana, Zambia and Zimbabwe. This follows on from the appointment of their first dedicated distributor for CD4 in Nigeria. All three countries require product registration, which has also commenced. Once completed, this will allow business to business sales to commence through the Company's distributors. The three countries have a high prevalence of people living with HIV and have been priortised on that basis.

Colin King, CEO of Omega commented: "I am pleased to see our commercialisation plan for CD4 taking shape as this is key part of our strategy to delivering shareholder value. This also provides further evidence that our CD4 test (the world's first true point-of-care test) will make a significant difference to people living with HIV in resource-poor environments."

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts:

 
 Omega Diagnostics Group PLC                                    Tel: 01259 763 030 
 Colin King, Chief Executive                              www.omegadiagnostics.com 
 Kieron Harbinson, Group Finance 
  Director 
 
 finnCap Ltd                                                    Tel: 020 7220 0500 
 Geoff Nash/James Thompson (Corporate 
  Finance) 
 Camille Gochez/ Abigail Wayne 
  (Corporate Broking) 
 
 Walbrook PR Limited                    Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus                                                   Mob: 07980 541 893 
 Lianne Cawthorne                                               Mob: 07584 391 303

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDEASXXFLFPEFF

(END) Dow Jones Newswires

July 18, 2018 02:00 ET (06:00 GMT)

Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Omega Diagnostics Charts.
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Omega Diagnostics Charts.